Federal jury rules Monsanto’s Roundup was a significant factor in man’s cancer

SAN FRANCISCO -- A federal jury in San Francisco today found that Monsanto’s best-selling weed killer, Roundup, was a significant factor in plaintiff Edward Hardeman’s non-Hodgkin’s lymphoma.

This case marks the first of three precedent-setting trials that could establish settlement standards for thousands of pending lawsuits across the country against Roundup manufacturer Monsanto, which is a branch of the Germany-based conglomerate Bayer. The plaintiffs allege that glyphosate, the main active ingredient in Roundup, is a cause of their cancer.

In a state court decision last year, a San Francisco jury awarded $289 million in damages to a former school groundskeeper with non-Hodgkins lymphoma after finding Monsanto failed to warn him about the potential health hazards of using Roundup.

In response, U.S. PIRG Education Fund’s Toxics Program director Kara Cook-Schultz released this statement:

“Ever since the World Health Organization determined glyphosate is a probable carcinogen, we have been warning consumers that Roundup is a possible health risk. Today’s verdict reflects these concerns. 



Related News